Health CareStill being tested
Merck (MRK)
Foghorn reads the news on Merck and calls up or down only when a story is strong enough to move the stock, so most days there's no call. Every call is locked before the market reacts and graded here once its time is up.
Last close $149.54 on Fri, Oct 30 (IEX)
Calls for the next trading day1 of 1right, 100% of 1 call where the stock moved
Calls for the next 5 trading days—No graded calls for the next 5 trading days yet
Graded calls on MRK
Most recently judged first. Calls appear here once they're graded, and once every other call on the same news is graded too.- Judged Oct 30MRKMerckCalled Up · next dayhow sure: a bit better than evenThe news: Merck Lifts Outlook on a Lower Tax Rate: Rapid Earnings ReactionThe stock rose 2.2%Result: RightLocked Oct 29, 3:32 PM ET , before its first judged close
Fingerprint b1e487…c474da1e
b1e487a23962b57420fd4803a74704fddcb78eb533b3af17685fad02c474da1e
Recent news Foghorn read on MRK
- Merck (NYSE: MRK) lifts sales outlook midpoint but third-quarter GAAP EPS falls 12%Nov 1 · themarketsdaily.com · Guidance
- Regeneron Surges 12% as Sanofi Dupixent Windfall and Eylea HD Power Earnings Beat; Moderna Slides 2%, Merck Edges Higher, Pfizer Ticks UpOct 30 · 247wallst.com · Earnings
- Merck Lifts Outlook on a Lower Tax Rate: Rapid Earnings ReactionOct 29 · fool.com · Guidance
- Merck Raises 2026 Earnings Outlook After Keytruda Qlex Sales Beat EstimatesOct 29 · econotimes.com · Earnings
- Merck Stock: Earnings Beat, But Can Shares Outplay The Cancer Vaccine News?Oct 29 · investors.com · Earnings
- Merck 8-K: Results of operations (Item 2.02)Oct 29 · SEC filing · Earnings
- Keytruda Gets Full FDA Approval for TMB-High Solid Tumors, but a Stricter 13-Mutation Cutoff Narrows EligibilityOct 29 · medicaldaily.com · FDA decision
- New World ACCESS Consortium White Paper Finds U.S. Most-Favored-Nation Pricing Is Reshaping How Biopharma Plans Global LaunchesOct 28 · prnewswire.com · Product news
General market commentary, made the same way for everyone. It isn't investment advice or a recommendation to buy or sell MRK, and past accuracy does not promise future results.